The GI side effects from both compounds are manageable for most people, but they can be severe enough to require dose reduction or treatment discontinuation in a meaningful minority
Timelines are individual and we avoid promising specific numbers
Differences in exposure to ivermectin, life history, and genetic diversity of targeted organisms in field settings may influence the mechanisms of resistance that develop
Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous fmt
Do not drive or operate heavy machinery following your pre-bedtime injection
Clark 5 , David Liebeskind 6 , Ryan McTaggart 7 1 Revalesio, Tacoma, United States, 2 Northwestern University, Feinberg School of Medicine, Chicago, United States, 3 University of Pennsylvania, Philadelphia, United States, 4 Houston Methodist Hospital, Houston, United States, 5 Oregon Stroke Ctr at OHSU, Portland, United States, 6 University of California Los Angeles, Los Angeles, United States, 7 Rhode Island Hospital, Brown University, Providence, United States Background and Aims: RNS60, an experimental cytoprotective drug, showed preliminary signs of efficacy in the proof-of-concept Phase 2 RESCUE trial in participants with acute ischemic stroke 6), early antiplatelet use was associated with improved functional outcomes on mRS (0.85, 0.76-0.95) and less 7-day NIHSS deterioration (0.63, 0.41-0.98)
